Soriot Should Explain the Curious Case of AstraZeneca’s Non-DealAug 6, 2026AstraZeneca CEO Pascal Soriot faces scrutiny over rejecting a deal, maintaining a long-term R&D strategy over short-term acquisitions while targeting $80bn revenue by 2030.Soriot Should Explain the Curious Case of AstraZeneca’s Non-DealtheguardianTopic tracking2026-01-30AstraZeneca signs $18.5 billion weight-loss-drug deal with Chinese firm2026-07-27AstraZeneca CEO Urges Western Drugmakers to Move at 'Chinese Speed'2026-08-06Soriot Should Explain the Curious Case of AstraZeneca’s Non-DealFAQWhy does the article describe AstraZeneca's potential acquisition of Bristol-Myers Squibb as a 'curious non-deal'?+What core strategic principle has guided AstraZeneca’s success under CEO Pascal Soriot, according to the article?+